Does One Voriconazole Breakpoint Suit All Candida Species?

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2007 Jun 6

PMID 17548458

Citations 5

Authors

Maiken Cavling Arendrup

David W Denning

M A Pfaller

D J Diekema

J H Rex

Affiliations

Soon will be listed here.

Citing Articles

Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of....

Pfaller M, Messer S, Woosley L, Jones R, Castanheira M J Clin Microbiol. 2013; 51(8):2571-81.

PMID: 23720791 PMC: 3719648. DOI: 10.1128/JCM.00308-13.

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Pfaller M, Diekema D J Clin Microbiol. 2012; 50(9):2846-56.

PMID: 22740712 PMC: 3421803. DOI: 10.1128/JCM.00937-12.

Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.

Borman A, Szekely A, Palmer M, Johnson E J Clin Microbiol. 2012; 50(8):2639-44.

PMID: 22649009 PMC: 3421536. DOI: 10.1128/JCM.00913-12.

Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S J Clin Microbiol. 2011; 49(4):1274-9.

PMID: 21289155 PMC: 3122818. DOI: 10.1128/JCM.02437-10.

Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S J Clin Microbiol. 2010; 49(2):630-7.

PMID: 21159940 PMC: 3043502. DOI: 10.1128/JCM.02161-10.

References

Lutsar I, Hodges M, Tomaszewski K, Troke P, Wood N . Safety of voriconazole and dose individualization. Clin Infect Dis. 2003; 36(8):1087-8. DOI: 10.1086/374248. View

Colombo A, Nucci M, Park B, Nouer S, Arthington-Skaggs B, da Matta D . Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006; 44(8):2816-23. PMC: 1594610. DOI: 10.1128/JCM.00773-06. View

Denning D, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E . Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34(5):563-71. DOI: 10.1086/324620. View

Diekema D, Messer S, Brueggemann A, Coffman S, Doern G, Herwaldt L . Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002; 40(4):1298-302. PMC: 140380. DOI: 10.1128/JCM.40.4.1298-1302.2002. View

Arendrup M, Horn T, Frimodt-Moller N . In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection. 2002; 30(5):286-91. DOI: 10.1007/s15010-002-2131-0. View

Betts R, Rotstein C, Colombo A, Thompson-Moya L, Smietana J, Lupinacci R . Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347(25):2020-9. DOI: 10.1056/NEJMoa021585. View

Sandven P, Bevanger L, Digranes A, Haukland H, Mannsaker T, Gaustad P . Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006; 44(6):1977-81. PMC: 1489391. DOI: 10.1128/JCM.00029-06. View

Krause D, Reinhardt J, Vazquez J, Reboli A, Goldstein B, Wible M . Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004; 48(6):2021-4. PMC: 415613. DOI: 10.1128/AAC.48.6.2021-2024.2004. View

Boyd A, Modi S, Howard S, Moore C, Keevil B, Denning D . Adverse reactions to voriconazole. Clin Infect Dis. 2004; 39(8):1241-4. DOI: 10.1086/424662. View

10.

Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B . Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999; 28(5):1071-9. DOI: 10.1086/514731. View

11.

Morrell M, Fraser V, Kollef M . Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9):3640-5. PMC: 1195428. DOI: 10.1128/AAC.49.9.3640-3645.2005. View

12.

Arendrup M, Fuursted K, Gahrn-Hansen B, Jensen I, Knudsen J, Lundgren B . Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005; 43(9):4434-40. PMC: 1234080. DOI: 10.1128/JCM.43.9.4434-4440.2005. View

13.

Pfaller M, Diekema D, Rex J, Espinel-Ingroff A, Johnson E, Andes D . Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006; 44(3):819-26. PMC: 1393146. DOI: 10.1128/JCM.44.3.819-826.2006. View